BioSpace News Archive

U.S. Patent and Trademark Office Rejects IPR Challenge to Medtronic Patent Company Says No Final Determinations Have Been Made on Other Patents [25-September-2020] DUBLIN , Sept. 25, 2020 /PRNewswire/ -- Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim

The American Pharmacists Association issued the following statement after the Food and Drug Administration finalized the rule for the legal importation of drugs from Canada:

COVID-19 testing startup Curative, Inc. today announced the launch of a new COVID-19 study in the City of San Antonio.

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the following virtual investor conferences in October: Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the Jefferies Gene Therapy/Editing Virtual Summit, including a fi

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three and six-months ended June 30, 2020, which are also available on SEDAR ( www.sedar.com ). The Company reported revenue of $69,452 for the three months ended June 30, 2020, compared with revenue of $259,108 for the three months ended June 30, 2019. Revenue from SIAscopy™ of $31,029 for the second quarter was higher than

Alzheimer’s disease is the most common form of dementia with more than 40 million affected people worldwide. To this day, there are no existing therapies for the effective prevention or treatment of the disease

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of three new members to the company’s Board of Directors with immediate effect.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%,

Verve Therapeutics, a next-generation cardiovascular company, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Jefferies Virtual Gene Therapy/Editing Summit being held October 1-2, 2020.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages four months to less than six months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.